Quality of recovery in patients administered remimazolam versus those administered an inhalant agent for the maintenance of general anesthesia: a randomized control trial

• Published in: BMC anesthesiology 2022-07, Vol.22 (1), p.1-226, Article 226
• Main Authors: Song, Seung Woo, Jang, Yo Nam, Yoon, Min-Woo, Jeon, Yeong-Gwan
• Format: Article
• Language: English
• Subjects: Analysis; Anesthesia; Anesthesia Recovery Period; Benzodiazepines; Cardiac arrhythmia; Cholecystectomy; Drug dosages; Enrollments; Extubation; Fentanyl; General Anesthesia; Health care; Informed consent; Intravenous administration; Laparoscopy; Medical care; Medical centers; Nausea; Patient satisfaction; Patients; Postoperative Nausea and Vomiting; Quality management; Questionnaires; Remimazolam; Robotic surgery; Statistical analysis; Surgery; Vomiting
• ISSN: 1471-2253; 1471-2253
• DOI: 10.1186/s12871-022-01770-x

Background Remimazolam is a novel intravenous benzodiazepine that is appropriate for the maintenance of anesthesia. Quality of recovery is an important component of health care quality, but there is no published randomized control trial focused on the quality of recovery in patients undergoing total intravenous anesthesia with remimazolam. Methods This parallel-group, single-blind randomized control trial at a tertiary care medical center in South Korea was conducted to determine the difference in the quality of recovery between the patients administered remimazolam and those administered an inhalant anesthetic agent. A total of 168 patients aged 19-65 years who underwent elective laparoscopic cholecystectomy or robotic gynecologic surgery were considered for enrollment. Randomization was performed using sealed envelopes containing computer-generated random allocation sequences. Remimazolam was administered for the maintenance of anesthesia in the remimazolam group (Group R), and desflurane was administered in the desflurane group (Group D). The induction protocol and the target value of the bispectral index were identical in both groups. Patients were blinded to the drug that was administered until they finished the postoperative questionnaire. The main outcome measure was the decrement of the QoR-40 score on postoperative day 1 compared to the QoR-40 score on the day before surgery. Results A total of 165 patients were analyzed. The preoperative and postoperative global QoR-40 scores were 183 and 152 (IQR 173-192 and 136-169), respectively. The perioperative decrement of the global QoR-40 score was 29.96 [+ or -] 22.49. The decrement of the QoR-40 score was smaller in Group R than in Group D (26.99 versus 32.90, respectively; mean difference 5.91, 95% confidence interval -0.96-12.79). After adjustment for sex, the type of surgery and surgical time, the administration of remimazolam resulted in a 7.03-point (95% CI 0.35-13.72) less decrement of the QoR-40 score than desflurane. There were no severe adverse events in either group. Conclusion Total intravenous anesthesia maintained with remimazolam provides a better quality of recovery than anesthesia maintained with an inhalant agent in patients undergoing laparoscopic surgery. Additionally, postoperative nausea and vomiting were largely reduced with remimazolam. Trial registration KCT0006288, Clinical Research Information Service (CRIS), Republic of Korea Registration date: 23/06/2021 Keywords: Remimazola